Judah Frommer
Stock Analyst at Morgan Stanley
(3.17)
# 1,123
Out of 4,944 analysts
179
Total ratings
60%
Success rate
6.63%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $26.24 | -0.91% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $25.09 | +71.38% | 2 | May 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $69.40 | -82.71% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.95 | +168.16% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $32.21 | -31.70% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $6.62 | -9.37% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $71.83 | +47.57% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.24 | +211.39% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $1.79 | +626.26% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $2.43 | +23.46% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $3.00 | +1,233.33% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.26 | +935.86% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $46.91 | -36.05% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $17.26 | +33.26% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $48.68 | +2.71% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $19.89 | +608.90% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.10 | +119.51% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $25.39 | -13.33% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.40 | +9.38% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $6.82 | +17.30% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $22.73 | +102.38% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.89 | +270.37% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $14.83 | +270.87% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $122.97 | -62.59% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $101.76 | -51.85% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $977.12 | -62.13% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $78.69 | -60.60% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $82.04 | -7.36% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $115.47 | +57.62% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $115.03 | -6.98% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $135.24 | -29.75% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $18.97 | -5.11% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $138.12 | -16.02% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $103.32 | -63.22% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $146.71 | -85.00% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $70.49 | -50.35% | 9 | Apr 29, 2020 |
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $26.24
Upside: -0.91%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $25.09
Upside: +71.38%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $69.40
Upside: -82.71%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.95
Upside: +168.16%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $32.21
Upside: -31.70%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $6.62
Upside: -9.37%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $71.83
Upside: +47.57%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.24
Upside: +211.39%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $1.79
Upside: +626.26%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.43
Upside: +23.46%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $3.00
Upside: +1,233.33%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.26
Upside: +935.86%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $46.91
Upside: -36.05%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $17.26
Upside: +33.26%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $48.68
Upside: +2.71%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $19.89
Upside: +608.90%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.10
Upside: +119.51%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $25.39
Upside: -13.33%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.40
Upside: +9.38%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $6.82
Upside: +17.30%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $22.73
Upside: +102.38%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.89
Upside: +270.37%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $14.83
Upside: +270.87%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $122.97
Upside: -62.59%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $101.76
Upside: -51.85%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $977.12
Upside: -62.13%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $78.69
Upside: -60.60%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $82.04
Upside: -7.36%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $115.47
Upside: +57.62%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $115.03
Upside: -6.98%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $135.24
Upside: -29.75%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $18.97
Upside: -5.11%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $138.12
Upside: -16.02%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $103.32
Upside: -63.22%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $146.71
Upside: -85.00%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $70.49
Upside: -50.35%